{
  "docId": "019de075-d132-769f-97bd-4a840dd24899",
  "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 56,
  "pageCount": 56,
  "prevPage": 55,
  "nextPage": null,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "The slide uses a scatter plot to show correlation between Cyno and Human half-lives, and bar charts to compare ADA (Anti-Drug Antibody) rates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/56",
  "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899",
  "deckJsonHref": "/decks/019de075-d132-769f-97bd-4a840dd24899.json",
  "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-56",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.38,
        "x": 0.08,
        "y": 0.8
      },
      "kind": "callout",
      "text": "Extent of half-life extension dependent on target (soluble vs. membrane bound)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac8a576d-0a63-4018-9469-205f7fa977bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "chart",
      "text": "ADA rates are similar for YTE and non-YTE antibodies",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0c98ab3-cea1-4e05-a352-37480702bedb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "YTE mAbs have extended half-lives in NHPs and humans",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "033fb865-1d6c-4f15-a2bd-cabb63cf3b8e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Source: 1) Rocca, A, et al. Int J of Mol Sci, 2021; 2) Domachowske NEJM 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "062d484d-89b3-42f5-87cb-c1dd9c2a737d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "YTE technology shown to significantly prolong half-life and without increasing immunogenicity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5970917b-92e0-4e46-adf9-7b95ff539c64",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "b585621c-2456-4f5b-8a0f-e9ddb9086eb0",
      "evidence": "chart/scatter: YTE mAbs have extended half-lives in NHPs and humans chart/bar-grouped: ADA rates are similar for YTE and non-YTE antibodies",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 56,
      "from": 45,
      "beatId": "a269a747-0743-41c8-a64a-96220e98956c",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines the potential impact and next steps for Spyre's pipeline.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}